<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Mass Tort News &amp; Updates | mass-torts.com</title>
    <link>https://mass-torts.com/news</link>
    <description>Latest news, settlement updates, and litigation developments in mass tort cases across the United States.</description>
    <language>en-us</language>
    <lastBuildDate>Sun, 05 Apr 2026 06:28:05 GMT</lastBuildDate>
    <atom:link href="https://mass-torts.com/rss.xml" rel="self" type="application/rss+xml"/>
    <item>
      <title>U.S. Court Bars Key Law Firm From J&amp;J Talc Litigation</title>
      <link>https://mass-torts.com/news#jj-talc-law-firm-barred</link>
      <guid isPermaLink="false">jj-talc-law-firm-barred</guid>
      <pubDate>Fri, 27 Mar 2026 00:00:00 GMT</pubDate>
      <category>Litigation Update</category>
      <description>A federal court has removed Beasley Allen from leadership in the Johnson &amp; Johnson talc litigation after finding the firm improperly collaborated with a former J&amp;J attorney during settlement negotiations.</description>
    </item>
    <item>
      <title>Jury Finds J&amp;J Baby Powder Caused Fatal Ovarian Cancer in Philadelphia Trial</title>
      <link>https://mass-torts.com/news#jj-talc-philadelphia-verdict</link>
      <guid isPermaLink="false">jj-talc-philadelphia-verdict</guid>
      <pubDate>Tue, 24 Mar 2026 00:00:00 GMT</pubDate>
      <category>Verdict</category>
      <description>A Pennsylvania jury awarded damages to the family of a woman who died of ovarian cancer linked to talcum powder use, marking the first Philadelphia talc ovarian cancer verdict and adding pressure on Johnson &amp; Johnson as 69,000+ cases remain pending.</description>
    </item>
    <item>
      <title>Judge Throws Out $950 Million Punitive Damages Award Against J&amp;J in Talc Trial</title>
      <link>https://mass-torts.com/news#jj-talc-punitive-damages-reversed</link>
      <guid isPermaLink="false">jj-talc-punitive-damages-reversed</guid>
      <pubDate>Mon, 16 Mar 2026 00:00:00 GMT</pubDate>
      <category>Litigation Update</category>
      <description>A judge has vacated the $950 million punitive damages portion of a talc verdict against Johnson &amp; Johnson, ruling there was insufficient evidence that the company knew of asbestos contamination or acted with malice.</description>
    </item>
    <item>
      <title>Q1 2026 MDL Snapshot: 158 Active Dockets, Nearly 198,000 Pending Cases</title>
      <link>https://mass-torts.com/news#mdl-trends-q1-2026</link>
      <guid isPermaLink="false">mdl-trends-q1-2026</guid>
      <pubDate>Wed, 11 Mar 2026 00:00:00 GMT</pubDate>
      <category>Industry Analysis</category>
      <description>A comprehensive analysis of Q1 2026 mass tort trends reveals 158 active MDLs with 197,965 pending cases, with 95% of cases concentrated in the top 25 dockets. Pharmaceutical and medical device litigation continue to dominate.</description>
    </item>
    <item>
      <title>DOJ Approves $175 Million in New Camp Lejeune Settlements</title>
      <link>https://mass-torts.com/news#camp-lejeune-doj-175m-settlements</link>
      <guid isPermaLink="false">camp-lejeune-doj-175m-settlements</guid>
      <pubDate>Tue, 10 Mar 2026 00:00:00 GMT</pubDate>
      <category>Settlement Update</category>
      <description>The Department of Justice has approved 649 new settlements totaling $175 million for Camp Lejeune water contamination victims. The DOJ has now paid over $700 million total, though thousands of claims remain pending.</description>
    </item>
    <item>
      <title>Hair Relaxer Lawsuits Surge Past 11,000 Cases as Daubert Deadline Approaches</title>
      <link>https://mass-torts.com/news#hair-relaxer-mdl-11000-cases</link>
      <guid isPermaLink="false">hair-relaxer-mdl-11000-cases</guid>
      <pubDate>Sun, 08 Mar 2026 00:00:00 GMT</pubDate>
      <category>Litigation Update</category>
      <description>MDL-3060 continues to grow at roughly 247 new cases per month. Daubert motions on expert scientific testimony are due April 1, 2026, as bellwether trial preparation targets 2027.</description>
    </item>
    <item>
      <title>Bayer&apos;s $7.25 Billion Roundup Class Settlement Gets Preliminary Court Approval</title>
      <link>https://mass-torts.com/news#roundup-725b-settlement-approved</link>
      <guid isPermaLink="false">roundup-725b-settlement-approved</guid>
      <pubDate>Thu, 05 Mar 2026 00:00:00 GMT</pubDate>
      <category>Settlement Update</category>
      <description>A Missouri Circuit Court judge has granted preliminary approval to Bayer&apos;s proposed $7.25 billion class action settlement to resolve current and future Roundup cancer claims. A final approval hearing is set for July 2026, with roughly 65,000 cases still pending.</description>
    </item>
    <item>
      <title>GLP-1 Vision Loss Lawsuits Advance in MDL 3163</title>
      <link>https://mass-torts.com/news#glp1-ozempic-mdl-3163-update</link>
      <guid isPermaLink="false">glp1-ozempic-mdl-3163-update</guid>
      <pubDate>Wed, 04 Mar 2026 00:00:00 GMT</pubDate>
      <category>Emerging Litigation</category>
      <description>Lawsuits alleging that semaglutide drugs (Ozempic, Wegovy) cause non-arteritic anterior ischemic optic neuropathy (NAION) and permanent vision loss are progressing in MDL 3163, a newly formed federal multidistrict litigation.</description>
    </item>
    <item>
      <title>Hernia Mesh Litigation: March 2026 Settlement Update</title>
      <link>https://mass-torts.com/news#hernia-mesh-march-2026-update</link>
      <guid isPermaLink="false">hernia-mesh-march-2026-update</guid>
      <pubDate>Sun, 01 Mar 2026 00:00:00 GMT</pubDate>
      <category>Litigation Update</category>
      <description>Hernia mesh lawsuits against manufacturers including C.R. Bard and Ethicon continue to move through the courts with ongoing settlement negotiations and bellwether trial scheduling in multiple MDL dockets.</description>
    </item>
    <item>
      <title>Drug Makers Agree Dupixent Cancer Lawsuits Should Be Centralized in MDL</title>
      <link>https://mass-torts.com/news#dupixent-cancer-mdl-formation</link>
      <guid isPermaLink="false">dupixent-cancer-mdl-formation</guid>
      <pubDate>Wed, 25 Feb 2026 00:00:00 GMT</pubDate>
      <category>Emerging Litigation</category>
      <description>Manufacturers have agreed that growing claims linking the allergy and eczema drug Dupixent to T-cell lymphoma should be consolidated into a new multidistrict litigation for coordinated pretrial proceedings.</description>
    </item>
  </channel>
</rss>
